Last reviewed · How we verify
Acecamycin (miocamycin)
Acecamycin (generic name: miocamycin) is a miocamycin drug. It is currently in unknown development.
Miocamycin works by binding to the bacterial ribosome and preventing the synthesis of essential proteins.
Acecamycin is a small molecule with synonyms including 3'',9-DIACETYLMYDECAMYCIN, 9,3''-DI-O-ACETYLMIDECAMYCIN, and Miocamycin. It is a macrolide antibiotic with a spectrum of activity similar to Erythromycin, effective against bacteria such as Legionella pneumophila, Mycoplasma hominis, and Ureaplasma urealyticum.
At a glance
| Generic name | miocamycin |
|---|---|
| Drug class | miocamycin |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Think of it like a factory assembly line: miocamycin blocks the assembly of proteins, which are crucial for bacterial growth and survival. Without these proteins, the bacteria can't function properly and eventually die. This mechanism is specific to bacteria and doesn't affect human cells, which is why miocamycin is used as an antibiotic.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acecamycin CI brief — competitive landscape report
- Acecamycin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Acecamycin
What is Acecamycin?
How does Acecamycin work?
What is the generic name of Acecamycin?
What drug class is Acecamycin in?
What development phase is Acecamycin in?
Related
- Drug class: All miocamycin drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing